Combination antifungal therapy: The new frontier

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The past decade has seen a significant increase in the incidence of invasive fungal infections. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against many fungi in in vitro and animal studies. On the other hand, caution is still needed since some antifungal combinations have also demonstrated antagonistic activity. Well-controlled clinical trials are still required to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side-effect potential of combination regimens and the pharmacoeconomic impact these regimens may have.

Original languageEnglish (US)
Pages (from-to)115-139
Number of pages25
JournalFuture Microbiology
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Mycoses
Fungal Drug Resistance
Pharmaceutical Economics
Controlled Clinical Trials
Fungi
Mortality
Incidence
Therapeutics
Pharmaceutical Preparations
In Vitro Techniques
Invasive Fungal Infections

Keywords

  • Animal models
  • Antifungals
  • Aspergillosis
  • Candida
  • Combination therapy
  • In vitro susceptibility
  • Zygomycosis

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Combination antifungal therapy : The new frontier. / Vazquez, Jose Antonio.

In: Future Microbiology, Vol. 2, No. 2, 01.04.2007, p. 115-139.

Research output: Contribution to journalArticle

@article{da70d1c82d5d4767a7db10152709b0ad,
title = "Combination antifungal therapy: The new frontier",
abstract = "The past decade has seen a significant increase in the incidence of invasive fungal infections. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against many fungi in in vitro and animal studies. On the other hand, caution is still needed since some antifungal combinations have also demonstrated antagonistic activity. Well-controlled clinical trials are still required to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side-effect potential of combination regimens and the pharmacoeconomic impact these regimens may have.",
keywords = "Animal models, Antifungals, Aspergillosis, Candida, Combination therapy, In vitro susceptibility, Zygomycosis",
author = "Vazquez, {Jose Antonio}",
year = "2007",
month = "4",
day = "1",
doi = "10.2217/17460913.2.2.115",
language = "English (US)",
volume = "2",
pages = "115--139",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Combination antifungal therapy

T2 - The new frontier

AU - Vazquez, Jose Antonio

PY - 2007/4/1

Y1 - 2007/4/1

N2 - The past decade has seen a significant increase in the incidence of invasive fungal infections. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against many fungi in in vitro and animal studies. On the other hand, caution is still needed since some antifungal combinations have also demonstrated antagonistic activity. Well-controlled clinical trials are still required to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side-effect potential of combination regimens and the pharmacoeconomic impact these regimens may have.

AB - The past decade has seen a significant increase in the incidence of invasive fungal infections. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against many fungi in in vitro and animal studies. On the other hand, caution is still needed since some antifungal combinations have also demonstrated antagonistic activity. Well-controlled clinical trials are still required to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side-effect potential of combination regimens and the pharmacoeconomic impact these regimens may have.

KW - Animal models

KW - Antifungals

KW - Aspergillosis

KW - Candida

KW - Combination therapy

KW - In vitro susceptibility

KW - Zygomycosis

UR - http://www.scopus.com/inward/record.url?scp=34248654044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248654044&partnerID=8YFLogxK

U2 - 10.2217/17460913.2.2.115

DO - 10.2217/17460913.2.2.115

M3 - Article

C2 - 17661650

AN - SCOPUS:34248654044

VL - 2

SP - 115

EP - 139

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 2

ER -